Zobrazeno 1 - 10
of 275
pro vyhledávání: '"J Joseph Melenhorst"'
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 12, Iss 3 (2024)
Abstract
Externí odkaz:
https://doaj.org/article/ebf8d53d504e4816b81b4c7e7e4f4603
Autor:
Carl H June, David M Barrett, Stephan A Grupp, Rong Fan, Marcela V Maus, Zhiliang Bai, Stefan Lundh, Dongjoo Kim, Steven Woodhouse, Regina M Myers, Pablo G Camara, J Joseph Melenhorst
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 5 (2021)
Background Autologous T cells engineered to express a chimeric antigen receptor (CAR) specific for CD19 molecule have transformed the therapeutic landscape in patients with highly refractory leukemia and lymphoma, and the use of donor-generated allog
Externí odkaz:
https://doaj.org/article/d1c8e9cf34dd480380636e72e6720295
Autor:
Jie Xu, J. Joseph Melenhorst
Publikováno v:
Blood Science, Vol 3, Iss 2, Pp 59-61 (2021)
Externí odkaz:
https://doaj.org/article/20e3cecac062466d884e29814f70f740
Autor:
Fang Chen, Joseph A. Fraietta, Carl H. June, Zhongwei Xu, J. Joseph Melenhorst, Simon F. Lacey
Publikováno v:
Engineering, Vol 5, Iss 1, Pp 140-149 (2019)
Cancer is one of the leading causes of death worldwide. Recent advances in cellular therapy have demonstrated that this platform has the potential to give patients with certain cancers a second chance at life. Unlike chemical compounds and proteins,
Externí odkaz:
https://doaj.org/article/efc3dde1d79240f08fcbd718400b5236
Autor:
Christopher L. Nobles, Shantan Reddy, January Salas-McKee, Xiaojun Liu, Carl H. June, J. Joseph Melenhorst, Megan M. Davis, Yangbing Zhao, Frederic D. Bushman
Publikováno v:
Genome Biology, Vol 20, Iss 1, Pp 1-6 (2019)
Abstract Genome engineering methods have advanced greatly with the development of programmable nucleases, but methods for quantifying on- and off-target cleavage sites and associated deletions remain nascent. Here, we report an improvement of the GUI
Externí odkaz:
https://doaj.org/article/029e894e495a48feb0359649b71e6498
Autor:
McKensie A. Collins, In-Young Jung, Ziran Zhao, Kimberly Apodaca, Weimin Kong, Stefan Lundh, Joseph A. Fraietta, Arnon P. Kater, Clare Sun, Adrian Wiestner, J. Joseph Melenhorst
Publikováno v:
Cancer research communications, 2(9), 1089-1103
CD19-redirected chimeric antigen receptor (CAR) T cells have shown remarkable activity against B-cell cancers. While second-generation CARs induce complete remission in >80% of patients with acute lymphoblastic leukemia, similar monotherapy induces l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cde7d05f94cb09796a19ee8e58a5f27e
https://doi.org/10.1158/2767-9764.crc-22-0200
https://doi.org/10.1158/2767-9764.crc-22-0200
Autor:
Kavita M. Dhodapkar, Adam D. Cohen, Akhilesh Kaushal, Alfred L. Garfall, Renee Julia Manalo, Allison R. Carr, Samuel S. McCachren, Edward A. Stadtmauer, Simon F. Lacey, J. Joseph Melenhorst, Carl H. June, Michael C. Milone, Madhav V. Dhodapkar
Publikováno v:
Blood Cancer Discovery. 3:490-501
Chimeric antigen-receptor (CAR) T cells lead to high response rates in myeloma, but most patients experience recurrent disease. We combined several high-dimensional approaches to study tumor/immune cells in the tumor microenvironment (TME) of myeloma
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1a8f4143080e2a873e434dc2b50b1a43
https://doi.org/10.1158/2643-3230.bcd-22-0018
https://doi.org/10.1158/2643-3230.bcd-22-0018
Autor:
Caroline Diorio, Rawan Shraim, Regina Myers, Edward M. Behrens, Scott Canna, Hamid Bassiri, Richard Aplenc, Chakkapong Burudpakdee, Fang Chen, Amanda M. DiNofia, Saar Gill, Vanessa Gonzalez, Michele P. Lambert, Allison Barz Leahy, Bruce L. Levine, Robert B. Lindell, Shannon L. Maude, J. Joseph Melenhorst, Haley Newman, Jessica Perazzelli, Alix E. Seif, Simon F. Lacey, Carl H. June, David M. Barrett, Stephan A. Grupp, David T. Teachey
Publikováno v:
Clinical Cancer Research. 28:3804-3813
Purpose: To study the biology and identify markers of severe cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS) in children after chimeric antigen receptor T-cell (CAR T) treatment. Experimental Desig
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::35fa230d856563f2e452186b3a0a53ac
https://doi.org/10.1158/1078-0432.ccr-22-0822
https://doi.org/10.1158/1078-0432.ccr-22-0822
Autor:
Kristen B. Long, Regina M. Young, Alina C. Boesteanu, Megan M. Davis, J. Joseph Melenhorst, Simon F. Lacey, David A. DeGaramo, Bruce L. Levine, Joseph A. Fraietta
Publikováno v:
Frontiers in Immunology, Vol 9 (2018)
Chimeric antigen receptor (CAR)-engineered T cells represent a breakthrough in personalized medicine. In this strategy, a patient's own T lymphocytes are genetically reprogrammed to encode a synthetic receptor that binds a tumor antigen, allowing T c
Externí odkaz:
https://doaj.org/article/c58a0a7c53d24d00984a95067342ecb3
Autor:
J. Joseph Melenhorst, Adrian Wiestner, Clare Sun, Arnon P. Kater, Joseph A. Fraietta, Stefan Lundh, Weimin Kong, Kimberly Apodaca, Ziran Zhao, In-Young Jung, McKensie A. Collins
CD19-redirected chimeric antigen receptor (CAR) T cells have shown remarkable activity against B-cell cancers. While second-generation CARs induce complete remission in >80% of patients with acute lymphoblastic leukemia, similar monotherapy induces l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5cf3eb81a06f7fa8e57723956281e4e7
https://doi.org/10.1158/2767-9764.c.6550785
https://doi.org/10.1158/2767-9764.c.6550785
